Comparative Pharmacology
Head-to-head clinical analysis: CRIXIVAN versus TIVICAY PD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRIXIVAN versus TIVICAY PD.
CRIXIVAN vs TIVICAY PD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indinavir is a specific, potent, reversible inhibitor of HIV-1 protease. It binds to the active site of the viral protease, preventing the cleavage of viral polyprotein precursors into functional proteins, resulting in the formation of immature, non-infectious virions.
Tivicay PD (dolutegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits the catalytic activity of HIV-1 integrase, preventing the integration of viral DNA into host chromosomal DNA, which is essential for viral replication.
800 mg orally every 8 hours on an empty stomach (1 hour before or 2 hours after meals) or with a light meal.
50 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 1.8 to 2.5 hours in healthy adults; requires dosing every 8 hours.
Terminal elimination half-life is approximately 12-15 hours in adults, supporting once-daily dosing.
Primarily fecal (78-82%) with approximately 20% renal excretion of unchanged drug.
Primarily metabolized by UGT1A1 with minor CYP3A4; 53% of dose recovered in feces (30% as unchanged drug) and 31% in urine (18% as unchanged drug).
Category C
Category C
Antiretroviral
Antiretroviral, integrase inhibitor